Jeroen J.W.M. Janssen

Department of Hematology, VU University medical center

Affiliated withVU University medical center

Research Area

Biography

Jeroen J.W.M. Janssen has not added Biography.
If you are Jeroen J.W.M. Janssen and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 36	2018

Other Publications

Article	Year
Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells. Experimental cell research\| PubMed ID: 15350537	2004
Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile. Matrix biology : journal of the International Society for Matrix Biology\| PubMed ID: 17521897	2007
Towards cure of CML: why we need to know more about CML stem cells? Current stem cell research & therapy\| PubMed ID: 19492977	2009
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. American journal of hematology\| PubMed ID: 19658186	2009
Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Annals of hematology\| PubMed ID: 20383504	2010
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells. Haematologica\| PubMed ID: 20421276	2010
Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. Immunotherapy\| PubMed ID: 21463196	2011
Clinical validation of dried blood spot sampling in therapeutic drug monitoring of ciclosporin A in allogeneic stem cell transplant recipients: direct comparison between capillary and venous... Therapeutic drug monitoring\| PubMed ID: 23296096	2013
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch... Annals of hematology\| PubMed ID: 23572137	2013
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology ... European journal of cancer (Oxford, England : 1990)\| PubMed ID: 23876833	2013
Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia. BMC cancer\| PubMed ID: 24712728	2014
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. Haematologica\| PubMed ID: 26721801	2016
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of cancer research and clinical oncology\| PubMed ID: 28224300	2017
Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling. The Journal of pharmacy and pharmacology\| PubMed ID: 28643375	2017
Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival. European journal of haematology\| PubMed ID: 28718971	2017
Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia. Haematologica\| PubMed ID: 28860339	2017
Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival. Haematologica\| PubMed ID: 28860340	2017
Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation. BMC cancer\| PubMed ID: 29121889	2017
Patient satisfaction with information on oral anticancer agent use. Cancer medicine\| PubMed ID: 29168352	2018
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. Critical reviews in oncology/hematology\| PubMed ID: 29198338	2017
Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe. European journal of haematology\| PubMed ID: 29288559	2017